Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

Related Clinical Trial
A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals COPD Exacerbation Blood and Urine Biomarkers Study Alpha-1 Carrier Genomics Study Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype Study of ARO-AAT in Normal Adult Volunteers Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry Respreeza® Self-administration and Learning Program (AmAREtTI Study) Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Environment Effect on Six-Minute Walk Test Performance Alpha-1 Foundation DNA and Tissue Bank Alpha1-antitrypsin Deficiency Registry Alpha-1 Research Registry Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency Alpha-1 Coded Testing(ACT) Study Long-Term Follow-up Study of ADVM-043 Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency 4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency? Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation” EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency Alpha-1 Foundation Research Registry Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients Evaluate Efficacy and Safety of “Kamada-AAT for Inhalation” in Patients With AATD A Study of DCR-A1AT in Healthy Adult Volunteers and Patients With A1ATD-Associated Liver Disease Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor) Aralast alpha1-proteinase Inhibitor Surveillance Study Pharmacokinetic Study of ARALAST (Human Alpha1- PI) The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Brief Title

Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

Official Title

Single-Dose, Double-Blind, Crossover Study to Evaluate the Pharmacokinetic Comparability of ARALAST Fraction IV-1 Alpha1-Proteinase Inhibitor (ARALAST Fr. IV-1) and ARALAST

Brief Summary

      The primary purpose of this study is to characterize the pharmacokinetic profile of
      intravenous Aralast Fraction (Fr.) IV-1, a sterile, stable, lyophilized preparation of
      functionally intact human Alpha1- Proteinase Inhibitor (α1-PI). This pharmacokinetic study
      will be a randomized controlled clinical trial with a cross-over design. Twenty-four subjects
      will be enrolled into the study. Overall study duration will be approximately 6-8 months.

Study Phase

Phase 1

Study Type


Primary Outcome

Area Under the Curve/Dose

Secondary Outcome

 Total Area Under the Curve Per Dose


Alpha 1-Antitrypsin Deficiency


Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor

Study Arms / Comparison Groups

Description:  60 mg/kg


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

December 2005

Completion Date

June 2006

Primary Completion Date

June 2006

Eligibility Criteria

        Inclusion Criteria:

          -  The subject or subject´s legally authorized representative has provided written
             informed consent

          -  Subject is 18 years of age or older

          -  Subject has a documented, endogenous plasma Alpha1-PI level < 8 Micromolar

          -  Subject is of the genotype Pi*Z/Z, Pi*Z/Null, Pi*Null/Null, Pi*Malton/Z, or others,
             dependent on the approval by the Sponsor

          -  If the subject is female or of childbearing potential, the subject has a negative
             urine test for pregnancy within 7 days prior to first study product administration and
             agrees to employ adequate birth control measures for the duration of the study

          -  Laboratory results obtained at the screening visit, meeting the following criteria:

               -  Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) <= 2 times
                  the upper limit of normal (ULN)

               -  Serum total bilirubin <= 2 times ULN

               -  Proteinuria < +2 on dipstick analysis

               -  Serum creatinine <= 1.5 times ULN

               -  Absolute neutrophil count (ANC) >= 1500 cells/mm3

               -  Hemoglobin >= 10.0 g/dL

               -  Platelet count >= 10^5/mm3

          -  If the subject is treated with any respiratory medications, including inhaled
             bronchodilators and inhaled or oral corticosteroids, the subjects´ medication doses
             were unchanged for at least 14 days prior to first study product administration

          -  Nonsmoker for a minimum of 3 months prior to first study product administration

        Exclusion Criteria:

          -  The subject has received any Alpha1-PI augmentation therapy (including Aralast and
             investigational Alpha1-PIs, by any route including intravenous and inhaled) within 42
             days prior to first study product administration

          -  The subject has received an investigational drug or device within 1 month prior to
             first study product administration, or the subject is currently receiving an
             investigational drug

          -  The subject has a known selective immunoglobulin A (IgA) deficiency (IgA level < 15
             mg/dL) and/or antibody to IgA

          -  The subject has a pulmonary exacerbation or had a pulmonary exacerbation in the past
             14 days prior to first study product administration

          -  The subject is pregnant or lactating, or intends to become pregnant during the course
             of the study

          -  The subject has a clinically significant medical, psychiatric, or cognitive illness,
             or recreational drug/alcohol use that, in the opinion of the investigator, would
             affect subject safety or compliance




18 Years - N/A

Accepts Healthy Volunteers



Jeff Garrett, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Baxalta now part of Shire


 Baxter Healthcare, Ltd. (New Zealand), Baxter Healthcare Pty. Ltd. (Australia)

Study Sponsor

Jeff Garrett, MD, Principal Investigator, Middlemore Hospital, Otahuhu, Auckland, New Zealand

Verification Date

April 2020